SpineX has reported in a press release that a publication titled, “A pilot study of the effect of transcutaneous spinal cord stimulation on micturition-related brain activity and lower urinary tract symptoms after stroke”, has been accepted by the Journal of Urology.
The publication reports improved bladder function and restoration of brain activity associated with normal voiding in stroke survivors who completed the company’s SCONE therapy.
According to SpineX, this demonstrates that SCONE therapy corrects brain activity changes after stroke, bringing post-stroke brain activity associated with bladder control to a level similar to that of healthy individuals. This improved brain function is directly associated with clinically significant improvements in bladder function.
“This is a significant advancement in our research,” said SpineX co-founder and chief medical officer Evgeniy Kreydin (University of Southern California, Los Angeles, USA), who is also a leading author of the recent Journal of Urology paper. “We are able to show clinical evidence that our technology can make a difference in the lives of stroke patients.”
Improved bladder function is a high priority for stroke survivors, affording the ability to sleep for longer periods of time, drive longer distances and live fuller lives—all of which, the release adds, are important advances that align with SpineX’s mission to improve the lives of people with neurological conditions.
“We are moving forward rapidly with this technology,” Kreydin added. “Right now, we are recruiting for a clinical trial with our SCONE device in numerous locations in North America and India.”